Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Intrahepatic cholestasis in Bruton’s agammaglobulinemia receiving mesalamine for co-morbid Crohn’s disease

    Giovanni Clemente Actis1★, Rinaldo Pellicano2, Floriano Rosina2★ Corresponding author

    1. 1Department of Gastro-Hepatology, Ospedale Gradenigo, Corso Regina Margherita 8, 10153 Torino, Italy.
    2. 2Department of Gastroenterology, Ospedale San Giovanni Battista (Molinette), C. Bramante 88, 10126 Torino, Italy.

    CORRESPONDENCE

    Giovanni Clemente Actis

    Department of Gastro-Hepatology, Ospedale Gradenigo, Corso Regina Margherita 8, 10153 Torino, Italy.

    actis_g@libero.it

    Received: 03-08-2013; Revised: 15-11-2013; Accepted: 17-01-2014.

    Volume 5, Issue 2 · pp. 151–152 · PUBLISHED 2014 · DOI: 10.4103/0976-500X.130071

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    The salicylate derivatives mesalamines are used to treat both ulcerative colitis and Crohn’s disease. Mesalamines are almost devoid of toxicity, apart from very low figures of nephrotoxicity as derived from large population surveys. Indeed, meticulous analysis of the literature reveals some almost anecdotal cases of cholestatic hepatitis in inflammatory bowel disease (IBD) patients receiving these drugs. We recently encountered one of such patients and we thought it worth describing him, owing to the presence of a peculiar co-morbidity.

    KEYWORDS

      Open in new tab

      REFERENCES

      As published

      Showing references and in-text citations exactly as published.

        Cite this article

        SELECT FORMAT

        Actis, G. C., Pellicano, R., & Rosina, F. (2014). Intrahepatic cholestasis in Bruton’s agammaglobulinemia receiving mesalamine for co-morbid Crohn’s disease. Journal of Pharmacology and Pharmacotherapeutics, 5(2), 151–152. https://doi.org/10.4103/0976-500X.130071